Passage Bio (PASG) Stock Price, News & Analysis

Company Overview

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $0.73 to $0.79
• 50-Day Range: $0.47 to $1.13
• 52-Week Range: $0.45 to $1.79
• Volume: 347,562 shs
• Average Volume: 343,021 shs
• Market Capitalization: $48.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.75
• Consensus Rating: Buy

Passage Bio Stock Analysis - MarketRank™

Passage Bio scored higher than 61% of companies evaluated by MarketBeat, and ranked 457th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Passage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Passage Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Passage Bio are expected to grow in the coming year, from ($1.03) to ($0.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Passage Bio is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Passage Bio is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Passage Bio has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.38% of the float of Passage Bio has been sold short.

Short Interest Ratio / Days to Cover

Passage Bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Passage Bio has recently increased by 1.84%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Passage Bio does not currently pay a dividend.

Dividend Growth

Passage Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.38% of the float of Passage Bio has been sold short.

Short Interest Ratio / Days to Cover

Passage Bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Passage Bio has recently increased by 1.84%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.06

News Sentiment

Passage Bio has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Passage Bio this week, compared to 1 article on an average week.

Search Interest

21 people have searched for PASG on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Balanced

Insider Buying vs. Insider Selling

In the past three months, Passage Bio insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $165,230.00 in company stock and sold $188,319.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.

Percentage Held by Insiders

Only 4.30% of the stock of Passage Bio is held by insiders.

Percentage Held by Institutions

53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PASG Stock Analysis - Frequently Asked Questions

How have PASG shares performed this year?

Passage Bio's stock was trading at $1.01 at the start of the year. Since then, PASG stock has decreased by 22.5% and is now trading at $0.7831.
View the best growth stocks for 2024 here.

How were Passage Bio's earnings last quarter?

Passage Bio, Inc. (NASDAQ:PASG) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05.

When did Passage Bio IPO?

Passage Bio (PASG) raised $126 million in an initial public offering on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager.

Who are Passage Bio's major shareholders?

Passage Bio's top institutional shareholders include Vestal Point Capital LP (9.88%), Erste Asset Management GmbH (3.98%), Geode Capital Management LLC (0.82%) and Landscape Capital Management L.L.C. (0.09%). Insiders that own company stock include Lynx1 Capital Management Lp, Orbimed Advisors Llc, Mark S Forman, Alexandros Fotopoulos, Kathleen Borthwick, Simona King, Sandip Kapadia and Bruce A Goldsmith.
View institutional ownership trends.

How do I buy shares of Passage Bio?

Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Passage Bio investors own include Enovix (ENVX), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST), Globant (GLOB) and Luminar Technologies (LAZR).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 12/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PASG
• CUSIP: N/A
• CIK: 1787297
• Web: www.passagebio.com
• Phone: 267-866-0311
• Fax: N/A
• Employees: 130
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.75
• High Stock Price Target: $13.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +940.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-102,060,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -72.53%
• Return on Assets: -52.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.15
• Quick Ratio: 5.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.03 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 61,770,000
• Free Float: 59,111,000
• Market Cap: $45.99 million
• Optionable: Optionable
• Beta: 1.43